A photo of Henry Akinbi.

Attending Neonatologist, Neonatology and Pulmonary Biology

Member, Perinatal Institute

Professor, UC Department of Pediatrics



Board Certified

My Biography & Research


As a neonatologist, my clinical specialty is neonatology with specific interests in neonatal infections and blood transfusions. My research areas include toxicology, pharmacometrics and microbiome.

My research is a natural extension of my clinical practice because it promotes evidence-based diagnoses and therapy. One of my goals is to understand the role of early antibiotic exposure on the overall health of neonates. My research aims to increase our understanding and rationale for managing neonatal abstinence syndrome.

One of my accomplishments is the provision of a webinar for the College of Clinical Pharmacologists. My work has been published in several well-respected journals, including the Journal of Clinical Pharmacology, BMJ Open Quality, Scientific Reports, Journal of Parenteral and Enteral Nutrition, Pediatrics, Journal of Pediatrics and Journal of Immunology.

I have been with Cincinnati Children’s for more than 26 years. Collaborations with clinicians and non-clinicians are welcome.

Additional Languages


Clinical Interests

Neonatal infections; blood transfusions

Research Interests

Pharmacokinetis/pharmacodynamics of psychotropic medications in neonates; role of lysozyme in airway host defense

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Neonatology, Perinatal

Research Divisions

Neonatology, Pulmonary Biology, Developmental Biology

My Education

MD: University of Ife, Ile-Ife, Nigera, Africa, 1980.

Residency: Pediatrics, University of North Carolina at Chapel Hill, 1988-1991.

Neonatology Fellowship: Children's Hospital of Philadelphia, Philadelphia, PA, 1991-1994.

Certification: General Pediatrics, 1991; Recertification, 1998; Newborn Medicine, 1995; Recertification, 2002.

My Publications

Selected Publication

Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy. Euteneuer, JC; Kamatkar, S; Fukuda, T; Vinks, AA; Akinbi, HT. Journal of Clinical Pharmacology. 2019; 59:168-176.

Impact of Institutional Breastfeeding Support in Very Low-Birth Weight Infants. Ward, LP; Tonnis, R; Otuneye, AT; Clemens, N; Akinbi, H; Morrow, AL. Breastfeeding Medicine. 2021; 16:238-244.

Physiologic Indirect Response Modeling to Describe Buprenorphine Pharmacodynamics in Newborns Treated for Neonatal Opioid Withdrawal Syndrome. Mizuno, T; McPhail, BT; Kamatkar, S; Wexelblatt, S; Ward, L; Christians, U; Akinbi, HT; Vinks, AA. Clinical Pharmacokinetics. 2021; 60:249-259.

Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. van Hoogdalem, MW; McPhail, BT; Hahn, D; Wexelblatt, SL; Akinbi, HT; Vinks, AA; Mizuno, T. Expert Opinion on Drug Metabolism and Toxicology. 2021; 17:87-103.

Epidemiological Investigation on the Current Practice of Umbilical Cord Clamping in China. Zhu, J; Xie, Y; Wang, B; Wang, Y; Akinbi, H; Xie, L. American Journal of Perinatology. 2020.

Surfactant phospholipids act as molecular switches for premature induction of quorum sensing-dependent virulence in Pseudomonas aeruginosa. Kuang, Z; Bennett, RC; Lin, J; Hao, Y; Zhu, L; Akinbi, HT; Lau, GW. Virulence. 2020; 11:1090-1107.

Utilizing Pediatric Physiologically Based Pharmacokinetic Models to Examine Factors That Contribute to Methadone Pharmacokinetic Variability in Neonatal Abstinence Syndrome Patients. McPhail, BT; Emoto, C; Fukuda, T; Butler, D; Wiles, JR; Akinbi, H; Vinks, AA. Journal of Clinical Pharmacology. 2020; 60:453-465.

Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. Wiles, JR; Isemann, B; Mizuno, T; Tabangin, ME; Ward, LP; Akinbi, H; Vinks, AA. Journal of Pediatrics. 2020; 167:1214-20.e3.

Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone‐exposed neonates. Taleghani, AA; Isemann, BT; Rice, WR; Ward, LP; Wedig, KE; Akinbi, HT. 2019; 1:33-38.

Bacterial killing is enhanced by exogenous administration of lysozyme in the lungs. Epaud, R; Delestrain, C; Weaver, TE; Akinbi, HT. Revue de Pneumologie Clinique. 2019; 76:22-27.